BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38206083)

  • 21. Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus.
    Okuma HS; Iwasa S; Shoji H; Takashima A; Okita N; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y
    Anticancer Res; 2014 Sep; 34(9):5037-41. PubMed ID: 25202088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gallbladder neuroendocrine carcinoma diagnosis, treatment and prognosis based on the SEER database: A literature review.
    Cai XC; Wu SD
    World J Clin Cases; 2022 Aug; 10(23):8212-8223. PubMed ID: 36159526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of pretreatment contrast-enhanced computed tomography in esophageal neuroendocrine carcinoma: A multi-center follow-up study.
    Zhou Y; Hou P; Zha KJ; Wang F; Zhou K; He W; Gao JB
    World J Gastroenterol; 2020 Aug; 26(31):4680-4693. PubMed ID: 32884225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Poorer prognosis for neuroendocrine carcinoma than signet ring cell cancer of the colon and rectum (CRC-NEC): a propensity score matching analysis of patients from the Surveillance, Epidemiology, and End Results (SEER) database.
    Chen Y; Tu J; Zhou S; Fu J; Wang Q
    Int J Colorectal Dis; 2021 Apr; 36(4):745-756. PubMed ID: 33415449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A competing-risks nomogram and recursive partitioning analysis for cause-specific mortality in patients with esophageal neuroendocrine carcinoma.
    Zhang G; Wu B; Wang X; Li J
    Dis Esophagus; 2019 Dec; 32(11):. PubMed ID: 30715226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters.
    Crippa S; Partelli S; Bassi C; Berardi R; Capelli P; Scarpa A; Zamboni G; Falconi M
    Surgery; 2016 Mar; 159(3):862-71. PubMed ID: 26602841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
    Walter T; Tougeron D; Baudin E; Le Malicot K; Lecomte T; Malka D; Hentic O; Manfredi S; Bonnet I; Guimbaud R; Coriat R; Lepère C; Desauw C; Thirot-Bidault A; Dahan L; Roquin G; Aparicio T; Legoux JL; Lombard-Bohas C; Scoazec JY; Lepage C; Cadiot G;
    Eur J Cancer; 2017 Jul; 79():158-165. PubMed ID: 28501762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database.
    Wang J; Wei B; Albarracin CT; Hu J; Abraham SC; Wu Y
    BMC Cancer; 2014 Mar; 14():147. PubMed ID: 24589259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. THE PROGNOSIS OF THE DIFFERENT ESOPHAGEAL NEUROENDOCRINE CARCINOMA SUBTYPES: A POPULATION-BASED STUDY.
    Tustumi F; Marques SSB; Barros EF; Henriques AC; Waisberg J; Dias AR
    Arq Gastroenterol; 2022; 59(1):53-57. PubMed ID: 35442337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age-specific clinicopathological characteristics and prognostic analysis of neuroendocrine carcinomas of the gallbladder.
    Zhang Z; Guo T; Huang X; Xie P; Wang L; Yu Y
    Cancer Med; 2022 Feb; 11(3):641-653. PubMed ID: 34841738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy.
    Honma Y; Nagashima K; Hirano H; Shoji H; Iwasa S; Takashima A; Okita N; Kato K; Boku N; Murakami N; Inaba K; Ito Y; Itami J; Kanamori J; Oguma J; Daiko H
    Cancer Med; 2020 Jan; 9(2):595-604. PubMed ID: 31794158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological Profile of Pure Neuroendocrine Neoplasms of the Esophagus: A South Indian Center Experience.
    Babu Kanakasetty G; Dasappa L; Lakshmaiah KC; Kamath M; Jacob LA; Mallekavu SB; Rajeev LK; Haleshappa RA; Kadabur Nagendrappa L; Saldanha SC; Kumar RV
    J Oncol; 2016; 2016():2402417. PubMed ID: 27340404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Elvebakken H; Hjortland GO; Garresori H; Andresen PA; Janssen EAM; Vintermyr OK; Lothe IMB; Sorbye H
    J Neuroendocrinol; 2023 Apr; 35(4):e13256. PubMed ID: 37017614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroendocrine Carcinoma of Gall Bladder: A Series of 19 Cases with Review of Literature.
    Kamboj M; Gandhi JS; Gupta G; Sharma A; Pasricha S; Mehta A; Chandragouda D; Sinha R
    J Gastrointest Cancer; 2015 Dec; 46(4):356-64. PubMed ID: 26208508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Neuroendocrine carcinoma of cervix: a clinicopathologic study of 82 cases].
    Feng M; Zou J; Zhang Y; Sun L
    Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):328-333. PubMed ID: 29783797
    [No Abstract]   [Full Text] [Related]  

  • 36. Adjuvant Chemotherapy Versus Observation Following Resection for Patients With Nonmetastatic Poorly Differentiated Colorectal Neuroendocrine Carcinomas.
    Mao R; Li K; Cai JQ; Luo S; Turner M; Blazer D; Zhao H
    Ann Surg; 2021 Aug; 274(2):e126-e133. PubMed ID: 31478977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resection of primary lesion with chemotherapy improves the survival of patients with metastatic colorectal neuroendocrine carcinoma.
    Wang Q; Yin R; Tang W; Li C; Zheng H; Zhang X; Jin X; Ying M; Fu J
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Nov; 51(5):594-602. PubMed ID: 36581574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgical resection of the primary tumor leads to prolonged survival in metastatic pancreatic neuroendocrine carcinoma.
    Feng T; Lv W; Yuan M; Shi Z; Zhong H; Ling S
    World J Surg Oncol; 2019 Mar; 17(1):54. PubMed ID: 30898132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary esophageal adenosquamous carcinoma: a retrospective analysis of 24 cases.
    Zhang HD; Chen CG; Gao YY; Ma Z; Tang P; Duan XF; Ren P; Yue J; Yu ZT
    Dis Esophagus; 2014; 27(8):783-9. PubMed ID: 24127755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status.
    Eloubeidi MA; Desmond R; Arguedas MR; Reed CE; Wilcox CM
    Cancer; 2002 Oct; 95(7):1434-43. PubMed ID: 12237911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.